Abstract: Tumor treating fields (TTFields) can be delivered to a subject's body at higher field strengths by switching off one or more electrode elements in a transducer array that are overheating. This may be accomplished by using thermistors that sense the temperature of each electrode element. Portions of the wiring of each transducer array is shared between the electrode elements and the thermistors by using a plurality of conductors, each of which electrically connects (a) a pin of a connector, (b) a respective electrode element, and (c) a respective thermistor. In some embodiments, all of the thermistors are wired in series. In other embodiments, all the thermistors share a common connection.

Abstract: When electrodes are used to impose an electric field in target tissue within an anatomic volume (e.g., to apply TTFields to treat a tumor), the position of the electrodes can be optimized by generating a 3D map of electrical conductivity or resistivity of the anatomic volume. A location of the target tissue within the anatomic volume is identified, and a dipole is added to the 3D map at a location that corresponds to the target tissue. positions for the electrodes that maximize a potential attributable to the dipole are determined based on the 3D map of electrical conductivity or resistivity and the location of the dipole.

Abstract: Damage from autoimmune diseases can be prevented or minimized by positioning a plurality of electrodes in or on a subject's body, and applying an AC voltage between the plurality of electrodes so as to impose an alternating electric field through the tissue that is being attacked by the autoimmune disease and/or draining lymph nodes associated with that tissue. The frequency and field strength of the alternating electric field are selected such that the alternating electric field inhibits proliferation of T cells in the tissue to an extent that reduces damage that is caused by the autoimmune disease.

Abstract: When electrodes are used to impose an electric field in target tissue within an anatomic volume (e.g., to apply TTFields to treat a tumor), the position of the electrodes can be optimized by obtaining electrical conductivity measurements in an anatomic volume and generating a 3D map of the conductivity directly from the obtained electrical conductivity or resistivity measurements, without segmenting the anatomic volume into tissue types. A location of the target tissue is identified within the anatomic volume, and the positions for the electrodes are determined based on the 3D map of electrical conductivity and the position of the target tissue.

Abstract: Tumor Treating Fields (TTFields) can be used to treat tumors (and/or prevent metastases) in or near a person's neck by affixing a first transducer array (i.e., a set of electrode elements) to the person's head and affixing a second transducer array to the person's chest. Subsequently, an AC voltage at a desired frequency (e.g., 100-300 kHz) is applied between the first transducer array and the second transducer array. This induces an electric field that is strong enough to be effective (e.g., greater than 1 V/cm) in most of the person's neck. In some embodiments, the center of the first transducer array is positioned on the vertex of the head or on an upper surface of the person's head. In some embodiments, the second set of electrode elements is positioned immediately below the base of the neck.

Abstract: Tumors inside a person's head (e.g., brain tumors) can be treated using tumor treating fields (TTFields) by positioning capacitively coupled electrodes on opposite sides of the tumor, and applying an AC voltage between the electrodes. Unlike the conventional approach (in which all of the electrodes are positioned on the person's scalp) at least one of the electrodes is implemented using an implanted apparatus. The implanted apparatus includes a rigid substrate shaped and dimensioned to replace a section of the person's skull. At least one electrically conductive plate is affixed to the inner side of the rigid substrate, and a dielectric layer is disposed on the inner side of the conductive plate or plates. An electrically conductive lead is used to apply an AC voltage to the conductive plate or plates.

Abstract: The spreading of cancer cells in a target region can be inhibited by imposing a first AC electric field in the target region for a first interval of time, with a frequency and amplitude selected to disrupt mitosis of the cancer cells; and imposing a second AC electric field in the target region for a second interval of time, with a frequency and the amplitude selected to reduce motility of the cancer cells. The amplitude of the second AC electric field is lower than the amplitude of the first AC electric field.

Abstract: Tumors can be treated with an alternating electric field. The size of cells in the tumor is determined prior to the start of treatment by, for example, biopsy or by inverse electric impedance tomography. A treatment frequency is chosen based on the determined cell size. The cell size can be determined during the course of treatment and the treatment frequency is adjusted to reflect changes in the cell size. A suitable apparatus for this purpose includes a device for measuring the tumor impedance, an AC signal generator with a controllable output frequency, a processor for estimating the size of tumor cells and setting the frequency of the AC signal generator based thereon, and at least one pair of electrodes operatively connected to the AC signal generator such that an alternating electric field is applied to the tumor.

Abstract: The spreading of cancer cells in a target region can be inhibited by imposing a first AC electric field in the target region for a first interval of time, with a frequency and amplitude selected to disrupt mitosis of the cancer cells; and imposing a second AC electric field in the target region for a second interval of time, with a frequency and the amplitude selected to reduce motility of the cancer cells. The amplitude of the second AC electric field is lower than the amplitude of the first AC electric field.

Abstract: A data transfer apparatus (“DTA”) connects to the field generator in a TTFields therapy system using the same connector on the field generator that is used to connect a transducer interface to the field generator. The field generator automatically determines whether the transducer interface or the DTA is connected to it. When the transducer interface is connected to the field generator, the field generator operates to deliver TTFields therapy to a patient. On the other hand, when the DTA is connected to the field generator, the field generator transfers patient-treatment data to the DTA, and the DTA accepts the data from the field generator. After the field generator and the DTA have been disconnected, the DTA transmits the data to a remote server, e.g., via the Internet or via cellular data transmission.

Abstract: Methods of reducing the viability of cancer cells, preventing cancer cells of a subject from developing resistance to TTFields, and restoring sensitivity of cancer cells to TTFields by recommending or prescribing a PTGER3 inhibitor to a subject and applying an alternating electric field to the cancer cells are provided. In some instances, sensitivity of cancer cells to TTFields can be restored with one or more PTGER3 inhibitors (e.g., NSAIDs, cox2 inhibitors).

Abstract: Tumors can be treated with an alternating electric field. The size of cells in the tumor is determined prior to the start of treatment by, for example, biopsy or by inverse electric impedance tomography. A treatment frequency is chosen based on the determined cell size. The cell size can be determined during the course of treatment and the treatment frequency is adjusted to reflect changes in the cell size. A suitable apparatus for this purpose includes a device for measuring the tumor impedance, an AC signal generator with a controllable output frequency, a processor for estimating the size of tumor cells and setting the frequency of the AC signal generator based thereon, and at least one pair of electrodes operatively connected to the AC signal generator such that an alternating electric field is applied to the tumor.

Abstract: Tumor treating fields (TTFields) can be delivered by implanting a plurality of sets of implantable electrode elements within a person's body. Temperature sensors positioned to measure the temperature at the electrode elements are also implanted, along with a circuit that collects temperature measurements from the temperature sensors. In some embodiments, an AC voltage generator configured to apply an AC voltage across the plurality of sets of electrode elements is also implanted within the person's body.

Abstract: Methods of treating gastric cancer and reducing the viability of gastric cancer cells by administering folinic acid, fluorouracil, and oxaliplatin to a subject, and applying an alternating electric field to a target region of the subject are provided. In some instances, chemotherapy such as XELOX, FOLFOX and individual components thereof are administered to a subject followed by applying an alternating electric field to the subject.

Abstract: Cancer treatment using TTFields (Tumor Treating Fields) can be customized to each individual subject by obtaining cancer cells from the subject, determining an electrical characteristic (e.g., dielectrophoretic forces, cell membrane capacitance, etc.) of the cancer cells, determining a frequency for the TTFields based on the determined electrical characteristic, and treating the cancer by applying TTFields to the subject at the determined frequency. In addition, cancer treatment can be planned for each individual subject by obtaining cancer cells from the subject, determining an electrical characteristic of the cancer cells, predicting whether TTFields would be effective to treat the cancer based on the determined electrical characteristic, and treating the subject by applying TTFields if the prediction indicates that TTFields would be effective.

Abstract: To plan tumor treating fields (TTFields) therapy, a model of a patient's head is often used to determine where to position the transducer arrays during treatment, and the accuracy of this model depends in large part on an accurate segmentation of MRI images. The quality of a segmentation can be improved by presenting the segmentation to a previously-trained machine learning system. The machine learning system generates a quality score for the segmentation. Revisions to the segmentation are accepted, and the machine learning system scores the revised segmentation. The quality scores are used to determine which segmentation provides better results, optionally by running simulations for models that correspond to each segmentation for a plurality of different transducer array layouts.

Abstract: Cancer cells can be synchronized to the G2/M phase by delivering an anti-microtubule agent (e.g., paclitaxel or another taxane) to the cancer cells, and applying an alternating electric field with a frequency between 100 and 500 kHz to the cancer cells, wherein at least a portion of the applying step is performed simultaneously with at least a portion of the delivering step. This synchronization can be taken advantage of by treating the cancer cells with radiation therapy after the combined action of the delivering step and the applying step has increased a proportion of cancer cells that are in the G2/M phase. The optimal frequency and field strength will depend on the particular type of cancer cell being treated. For certain cancers, this frequency will be between 125 and 250 kHz (e.g., 200 kHz) and the field strength will be at least 1 V/cm.

Abstract: A transducer array for use in tumor-treating fields (TTFields) therapy is particularly suited for use in treating abdominal or thoracic cancers. The transducer array has features that increase its flexibility and adhesion to the patient's skin, including a branching configuration and a correspondingly branching top covering adhesive-backed layer. Additionally, a skin-level adhesive layer is provided beneath the flex circuit to which the electrode elements are attached, to help ensure thorough, lasting adhesion of the transducer array to the patient's skin over the course of treatment.

Abstract: Tumor treating fields (TTFields) can be delivered to a subject's body at higher field strengths by switching off one or more electrode elements that are overheating without switching off other electrode elements that are not overheating. This may be accomplished using a plurality of temperature sensors, with each of the temperature sensors positioned to sense the temperature at a respective electrode element; and a plurality of electrically controlled switches, each of which is wired to switch the current to an individual electrode element on or off. A controller input signals from the temperature sensors to determine the temperature at each of the electrode elements, and controls the state of the control input of each of the electrically controlled switches to selectively switch off the current or adjusted the duty cycle at any electrode element that is overheating.

Abstract: A 3D model of AC electrical conductivity of the head (or other body part) can be generated by obtaining both CT and MRI images of the head, and combining the CT and MRI images into a composite model that specifies a conductivity at each voxel of the composite model. Voxels in the composite model that correspond to bone (e.g., the skull) are derived from the CT image, and voxels that correspond to the brain (e.g., white matter, gray matter, etc.) are derived from the MRI image. In some embodiments, the 3D model of conductivity is used to determine the positions for the electrodes in TTFields (Tumor Treating Fields) treatment.